¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell cycle time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • reaction time
    ¹ÝÀÀ½Ã°£
  • reaction time crossover
    ¹ÝÀÀ½Ã°£±³Â÷
  • real time acquisition
    ½Ç½Ã°£È¹µæ
  • real time display
    ½Ç½Ã°£Ç¥½Ã
  • real time imaging
    ½Ç½Ã°£¿µ»ó
  • real time PCR
    ½Ç½Ã°£ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ
  • real time study
    ½Ç½Ã°£°Ë»ç
  • real time ultrasonography
    ½Ç½Ã°£ÃÊÀ½ÆÄÃÔ¿µ(¼ú)
  • recirculation time
    Àç¼øÈ¯½Ã°£
  • recovery time
    ȸº¹½Ã°£
  • retention time
    Á¤Ã¼½Ã°£
  • rise time
    »ó½Â½Ã°£
  • spin lattice relaxation time
    ½ºÇɰÝÀÚÀ̿Ͻð£
  • spin-spin relaxation time
    ½ºÇɽºÇÉÀ̿Ͻð£
  • survival time
    »ýÁ¸±â°£
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • cell line
    ¼¼Æ÷ÁÖ
  • giant cell pneumonia
    °Å´ë¼¼Æ÷Æó·Å
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • sickle cell trait
    ³´¼¼Æ÷¼ÒÁú, ³´ÀûÇ÷±¸Çü¼º¼ÒÁú
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
  • red cell distribution width
    ÀûÇ÷±¸ºÐÆ÷Æø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • maximum phonation time
    ÃÖÀå¹ß¼ºÁö¼Ó½Ã°£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • mean tidal time
    Æò±Õ¼øÈ¯½Ã°£
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • partial thromboplastin time
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • perception time
    Áö°¢½Ã°£, ÀνĽð£
  • person-time incidence rate
    »ç¶÷±â°£¹ß»ý·ü
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
  • polymerizing time
    ±»´Â½Ã°£, ÁßÇսð£
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • reaction time
    ¹ÝÀÀ½Ã°£
  • real time study
    ½Ç½Ã°£°Ë»ç
  • real time system
    ½Ç½Ã°£Ã¼°è
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • B cell differentiation factor (BCDF)
    B¼¼Æ÷ ºÐÈ­À¯¹ßÀÎÀÚ
  • B cell growth factor
    B ¼¼Æ÷¼ºÀåÀÎÀÚ
  • B cell growth factor (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
  • B cell hybridoma
    B¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • B cell lymphoma
    B¼¼Æ÷¸²ÇÁÁ¾
  • B cell stimulating factor (BSF)
    B¼¼Æ÷ ÀÚ±ØÀÎÀÚ
  • B cell study
    B ¼¼Æ÷°Ë»ç
  • B cell/lymphocyte
    B ¼¼Æ÷/¸²ÇÁ±¸
  • B-cell
    ºñ ¼¼Æ÷
  • C-cell
    C ¼¼Æ÷
  • CD4+ cell
    CD4+ ¼¼Æ÷
  • Cell adhesion molecules
    ¼¼Æ÷À¯ÂøºÐÀÚ
  • Chinese hamster ovary tumor cell
    Áß±¹ÇÔ½ºÅÍ ³­¼Ò¼¼Æ÷, CHO¼¼Æ÷
  • Graham cell
    ±×¶óÇÔ¼¼Æ÷
  • Granulosa cell
    °ú¸³¸·¼¼Æ÷(Î¨Ø£Ø¯á¬øà)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • vicious circle = v. cycle
    ¾Ç¼øÈ¯(ç÷âàü»)
  • vicious circle =v. cycle
    ¾Ç¼øÈ¯(ç÷âàü»).
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • beta cell insulin cell
    º£Å¸¼¼Æ÷ Àν´¸°¼¼Æ÷
  • bronchiolar cell clara cell
    ¼¼±â°üÁö¼¼Æ÷
  • cell to cell cooperation
    ¼¼Æ÷°£ÇùÁ¶ÀÛ¿ë(á¬øàÊàúððàíÂéÄ).
  • chief cell type i glomus cell
    °ú¸³¼¼Æ÷
  • clear cell basal cell carcinoma
    Åõ¸í¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
  • clear cell epinephrine cell
    ¹àÀº¼¼Æ÷ ¿¡Çdz×ÇÁ¸°¼¼Æ÷
  • cytotoxic T-cell ; killer T-cell
    (¼¼Æ÷)»ì(ÇØ) T¼¼Æ÷.
  • dark cell norepinephrine cell
    ¾îµÎ¿î¼¼Æ÷ ³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷
  • interstitial cell dark cell
    »çÀÌÁú¼¼Æ÷
  • interstitial cell leydigs cell
    »çÀÌÁú¼¼Æ÷
  • lupus erythematosus cell = LE cell
    È«¹Ý¼º ·çǪ½º¼¼Æ÷(¡­á¬øà)
  • neurolemmal cell [schwanns cell]
    ½Å°æÁý¼¼Æ÷
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Base of cell
    ¼¼Æ÷¹Ù´Ú
    [¿¾ ¿ë¾î] ¼¼Æ÷Àú
  • Cell organelles
    ¼¼Æ÷¼Ò±â°ü
    [¿¾ ¿ë¾î] ¼¼Æ÷¼Ò±â°ü
  • Axis of cell
    ¼¼Æ÷Ãà
    [¿¾ ¿ë¾î] ¼¼Æ÷Ãà
  • Parafollicular cell
    ¼ÒÆ÷°ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¹æ¼¼Æ÷
  • Follicular cell
    ¼ÒÆ÷¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¼¼Æ÷
  • Inner pillar cell
    ¼Ó±âµÕ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ÁÖ¼¼Æ÷
  • Inner sustentacular cell
    ¼Ó¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ÁöÁÖ¼¼Æ÷
  • Inner cell mass (Embryoblast)
    ¼Ó¼¼Æ÷µ¢ÀÌ [¹èÀÚ¸ðü]
    [¿¾ ¿ë¾î] ³»¼¼Æ÷±«
  • Inner cell mass [Embryoblast]
    ¼Ó¼¼Æ÷µ¢ÀÌ [¹èÀÚ¸ðü]
    [¿¾ ¿ë¾î] ³»ºÎ¼¼Æ÷±«
  • Inner phalangeal cell
    ¼Ó¼Õ°¡¶ô¼¼Æ÷
    [¿¾ ¿ë¾î] ³»Áö»ó¼¼Æ÷
  • Medullary endocrine cell
    ¼ÓÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¼öÁú³»ºÐºñ¼¼Æ÷
  • Inner hair cell
    ¼ÓÅм¼Æ÷
    [¿¾ ¿ë¾î] ³»À¯¸ð¼¼Æ÷
  • Internal nuclear layer [Bipolar cell layer]
    ¼ÓÇÙÃþ [µÎ±Ø¼¼Æ÷Ãþ]
    [¿¾ ¿ë¾î] ³»ÇÙÃþ(À̱ؼ¼Æ÷Ãþ)
  • Endocrine cell of pineal gland
    ¼Û°úü³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¼Û°úü³»ºÐºñ¼¼Æ÷
  • Pinealocyte [Clear cell]
    ¼Û°úü¼¼Æ÷
    [¿¾ ¿ë¾î] ¼Û°úü¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • visual cycle
    ½Ã°¢ÁÖ±â(ãÊÊÆñÎÑ¢)
  • absorption cell
    Èí¼ö¼Ò°ü (ýåâ¥á³Î·)
  • amplifier T cell
    Áõ½Ä T ¼¼Æ÷(ñòãÖ T á¬øà)
  • antigen presenting cell
    Ç׿øº¸À¯¼¼Æ÷(ù÷ê«ÜÁêóá¬øà)
  • APUD cell
    APUD ¼¼Æ÷(á¬øà)
  • argentaffin cell
    ¾Æ¸£Á¨Å¸ÇÉ ¼¼Æ÷(á¬øà)
  • autosynthetic cell
    ÀÚ°¡ÇÕ¼º¼¼Æ÷ (í»Ê«ùêà÷á¬øà)
  • barrier layer cell
    À庮Ãþ(î¡Ûúöµ) ¼¼Æ÷(á¬øà)
  • B cell
    B ¼¼Æ÷(á¬øà)
  • cell adhesion
    ¼¼Æ÷ºÎÂø(á¬øàÜõó·)
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ(á¬øàÜõó·ÝÂí­)
  • cell affinity
    ¼¼Æ÷ģȭ(á¬øàöÑûú)
  • cell blotting
    ¼¼Æ÷(á¬øà) ºí·ÔÆÃ
  • cell cloning
    ¼¼Æ÷(á¬øà) Ŭ·Î´×
  • cell coat
    ¼¼Æ÷(á¬øà)²®Áú
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • islet cell adenoma
    Ãéµµ¼¼Æ÷¼±Á¾
  • islet cell carcinoma
    µµ¼¼Æ÷¾ÏÁ¾
  • Langerhans' cell
    ¶û°Ô¸£Çѽº¼¼Æ÷
  • Langhans' glant cell
    ¶û±×Çѽº°Å¼¼Æ÷
  • large cell
    ´ë¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ¾ç¼¼Æ÷, ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ±¸¾ç¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mastoid air cell
    À¯µ¹ºÀ¼Ò
  • mastoid cell
    À¯(¾ç)µ¹(±â)ºÀ¼Ò
  • nerve cell
    ½Å°æ¼¼Æ÷
  • neuroepithelial cell
    ½Å°æ»óÇǼ¼Æ÷
  • neuroglial cell
    ½Å°æ¾Æ±³¼¼Æ÷, ½Å°æ±³¼¼Æ÷
  • olfactory cell
    Èİ¢(»óÇÇ)¼¼Æ÷, Èİ¢¼¼Æ÷
  • packed cell
    ÃæÀü¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
WCL Wenckebach cycle length; whole cell lysate
GC ganglion cell; gas chromatography; general circulation; general closure; general condition; generali...
MCT manual cervical traction; mean cell thickness; mean cell threshold; mean circulation time; mean corp...
MCD   1) Minimal Change Disease
  2) Menstrual Cycle Day
BRAC basic rest-activity cycle
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
APTT Activated Partial Thromboplastin Time
AT Activation time
AUC Area under concentration-time curve
ART Arm-retina time
AVP Arteriovenous passage time
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • alveolar cell carcinoma
    ÆóÆ÷ ¼¼Æ÷ ¾ÏÁ¾
  • Alzheimer's cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • Alzheimers cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • amplifying cell
    Áõ½Ä ¼¼Æ÷
  • angiotropic intravascular large cell lymphoma
    Ç÷°ü ¿µ¾ç¼º Ç÷°ü³» ´ë¼¼Æ÷ ¸²ÇÁÁ¾
  • anterior horn cell
    Àü°¢ ¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×ü ÀÇÁ¸ ¼¼Æ÷ ¸Å°³ ¼¼Æ÷ µ¶¼º, Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antitumor k cell
    Ç×Á¾¾ç k ¼¼Æ÷
  • anucleate cell
    ¹«ÇÙ ¼¼Æ÷
    ÇüÅÂÀûÀ¸·Î ºÐÈ­ÇÑ ±¸Á¶·Î¼­ÀÇ ÇÙÀ» °¡ÁöÁö ¾Ê´Â ¼¼Æ÷. ¼¼±ÕÀ̳ª ³²Á¶·ù¿¡¼­´Â ÇüÅÂÀûÀ¸·Î ¶Ñ·ÇÇÏ°Ô ºÐÈ­ÇÑ ÇÙÀÌ ¾ø´Ù. ÀÌ·¯ÇÑ ¼¼Æ÷¸¦ ÇÁ·ÎÄ«¸®¿ÀÆ®
  • APUD cell
    APUD ¼¼Æ÷
    amine
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º ±âÀú¼¼Æ÷ ¾Ï
  • B cell
    B ¼¼Æ÷
    °ñ¼ö¿¡¼­ Çü¼ºµÈ ¸²ÇÁ±¸, ÇüÁú ¼¼Æ÷·Î ÀüȯµÇ¾î Ç×ü¸¦ »ý¼º. ÃéÀåÀÇ ¶û°Ô¸£Çѽº ¼¶¿¡ ÀÖ´Â 4Á¾·ùÀÇ ¼¼Æ÷ Áß Çϳª·Î¼­ Àν¶¸°À» ºÐºñÇÑ´Ù.
  • B cell clone
    B ¼¼Æ÷ Ŭ·Ð
    Ŭ·ÐÀ̶õ ´ÜÀÏÀÇ ¼¼Æ÷¸¦ Á¶»óÀ¸·Î ÇÏ´Â 1±ºÀÇ ¼¼Æ÷¸¦ ¸»ÇÑ´Ù. µû¶ó¼­ B ¼¼Æ÷ Ŭ·ÐÀº ´ÜÀÏÀÇ B ¼¼Æ÷°¡ ºÐ¿­, Áõ½ÄÇÏ¿© Çü¼ºÇÑ B ¼¼Æ÷ Áý´ÜÀ» ¸»ÇÑ´Ù. ÀÌ °æ¿ì µ¿ÀÏÇÑ ¸é¿ª ±Û·ÎºÒ¸° V À¯ÀüÀÚ¸¦ ¹ßÇöÇϰí ÀÖ´Â B ¼¼Æ÷·Î »ý°¢ÇÒ ¼ö ÀÖ´Ù. Á¤»óÀÇ B¼¼Æ÷´Â ¾Æ´ÏÁö¸¸ ¼¼Æ÷À¶ÇÕ¹ýÀ¸·Î ¾ò¾îÁø B ¼¼Æ÷ À¶ÇÕÁ¾µµ ¶Ç B¼¼Æ÷ Ŭ·ÐÀ̶ó°í ºÒ¸®¿ì´Â ¼ö°¡ ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
clotting time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
coagulation time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
collision time <radiobiology> Typical time which passes between two consecutive collision events for a given particle. Inverse of the collision frequency, equal to the mean free path divided by the particle's velocity. In plasmas, the (Coulomb) collision time decreases with increasing density, and increases with increasing temperature.
(09 Oct 1997)
whole blood coagulation time Measurement of the time required by whole blood to produce a visible clot. Factors that could influence the test are all but III, vii, and xiii. Activation may be by contact with the glass tube or exposure to diatomaceous earth. Delay of onset of coagulation may be achieved by use of nonwettable plastic or silicone-coated glass tubes. It is used for monitoring heparin therapy and as a bedside screening test for deficiencies in the intrinsic coagulation pathway. "activated coagulation time" is sometimes referred to as act.
(12 Dec 1998)
confinement time <radiobiology> There are several types. The general definition is tau = [total]/[loss per unit time], hence Tau_E = [total energy]/[energy loss per unit time]. Tau_[E, N,.] is the amount of time the plasma is contained (for example, by magnetic fields) before its [energy (E), particles (N or P)] leak / dissipate away. The different types are, in general, similar but not equal. (N.B., Tau_E is NOT electron confinement time!)
(09 Oct 1997)
continuous time model <epidemiology> A model in which the system changes continuously over time. Derivatives (e.g. DY/dt ) are the mathematical formalism for describing such continuous change. The differential equation which embodies a model provides the values of these derivatives at any particular time point; calculus or a computer can then be used to move the state of the model forwards in time.
Continuous models have the advantage over discrete time models in that they are more amenable to algebraic manipulation, although they are slightly harder to implement on a computer.
The same as a differential equation model.
(05 Dec 1998)
half-time The time, in a first-order chemical (or enzymic) reaction, for half of the substance (substrate) to be converted or to disappear.
Compare: half-life.
(05 Mar 2000)
prothrombin time Measurement of clotting time of plasma recalcified in the presence of excess tissue thromboplastin. Factors measured are fibrinogen, prothrombin, and factors v, vii, and x. It is used for monitoring anticoagulant therapy with coumarins.
(12 Dec 1998)
sensation time The minimal time a visual image must be exposed in order to be perceived.
(05 Mar 2000)
H-R conduction time Conduction of the cardiac impulse through the ventricular myocardium, represented by the QRS complex in the electrocardiogram. H-R conduction time is from the onset of the first high frequency component of the His bundle electrogram to the onset of the QRS complex of the surface electrocardiogram (normally 43 &plusmn; 12 msec); H-V conduction time is from the onset of the first high frequency component of the His bundle electrogram to the onset of the ventricular electrogram (normally approximates the H-R interval but may be a little shorter).
Synonym: ventricular conduction.
(05 Mar 2000)
H-V conduction time Conduction of the cardiac impulse through the ventricular myocardium, represented by the QRS complex in the electrocardiogram. H-R conduction time is from the onset of the first high frequency component of the His bundle electrogram to the onset of the QRS complex of the surface electrocardiogram (normally 43 &plusmn; 12 msec); H-V conduction time is from the onset of the first high frequency component of the His bundle electrogram to the onset of the ventricular electrogram (normally approximates the H-R interval but may be a little shorter).
Synonym: ventricular conduction.
(05 Mar 2000)
sinoatrial conduction time <cardiology, physiology> The time required for an impulse to travel from the sinoatrial node to the atrium; estimated indirectly during asystole by halving the average interval from the premature beat to the following normal sinus beat of the atrium.
(05 Mar 2000)
sinoatrial recovery time <cardiology, physiology> Interval from the last paced P wave to the first succeeding spontaneous P wave (after 2 to 5 minutes of right atrial pacing at 120 to 140 beats per minute, and when expressed as percentage of control cycle length, it normally ranges from 115 to 159%).
(05 Mar 2000)
space-time clustering A statistically significant excess of cases of a disease, occurring within a limited space-time continuum.
(12 Dec 1998)
Stypven time test A test measuring the clotting time of plasma after addition of Russell's viper venom, useful in evaluating patients with deficiencies in factor X.
Origin: Trade name styptic + venom
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Father Time
    ½Ã°£ ÇҾƹöÁö
  • Greenwich (Mean(Civil)time
    ±×¸®´ÏÄ¡ Ç¥ÁؽÃ
  • Greenwich Mean Time
    ±×¸®´ÏÄ¡ Ç¥ÁؽÃ
  • Hawaii time
    =Hawaiian Standard TimeÇÏ¿ÍÀÌ Ç¥ÁؽÃ(GMEº¸´Ù 10½Ã°£ ´Ê°í ½Ã°£´ë´Â Alaska Time¿Í °°À½
  • Pacific(Standard) Time
    (¹Ì±¹ÀÇ) ÅÂÆò¾ç Ç¥ÁؽÃ
  • T-time
    ·ÎÄÏ ¹ß»ç ½Ã°£
  • Time Square
    New York ½ÃÀDZØÀå°¡
  • access time
    È£Ãâ½Ã°£(±â¾ï ÀåÄ¡¿¡ Á¤º¸¸¦ ±â·Ï,ÇØµ¶ÄÉ Çϱâ À§ÇÑ ½Ã°£);ÄÄÇ»ÅÍ¿ë¾î
  • apparent time
    (ÇØ½Ã°èµîÀÇ)žçÀÇ À§Ä¡·Î ÃøÁ¤Çϴ½ð£
  • atomic time clock
    ¿øÀÚ ¿¬´ë ½Ã°è
  • atonic time clock
    ¿øÀÚ¿¬´ë
  • bad time
    °ï°æ
  • church time
    ¿¹¹è ½Ã°£
  • close time
    =CLOSE SEASON
  • closing time
    ÆóÁ¡(Á¾¾÷)½Ã°£
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á